Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was developed using domains of viral structural proteins and a polyprotein protease. Specifically, the COVID-19 infection relies... Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these engineered minigenes to express viral proteins, modify artificial antigen presenting...
- Mechanism
- Curator reviewed
Pharmacologically active on T-cell surface glycoprotein CD3
- Also known as
- aAPC · artificial antigen -Pathogen-specific vaccine
- Code names
- Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
What you can answer from here — as of July 18, 2026
Which companies are running trials of Pathogen-specific aAPC, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account